As of 5 Nov 2026, Skybiotech Healthcare is loss-making on a trailing 12-month basis, with a net loss of ₹1.67 Cr, so it has no P/E ratio. The share price is ₹114.50, 45% below its 52-week high. Debt is 0.91× equity. It is a small-cap company with a market cap of ₹22 Cr; the shares fell 30% over the past year.
- ₹115.00
- ₹115.00
- ₹114.50
- ₹114.50
- 50
Health check
- ReturnsWeak
−29.7% over the past year.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityNegative
ROCE -9.4%.
- Balance sheetStretched
Debt 0.91× equity, operating profit doesn’t cover interest.
- Red flags5 to check
Loss-making over the last twelve months.
Key metrics
- Market cap
- ₹22 Cr
- Small cap
- P/E
- n/a
- Price to book
- 2.39
- Book value ₹47.96
- Dividend yield
- 0.00%
- ROE
- −13.2%
- Return on equity
- ROCE
- −9.4%
- Return on capital employed
- Debt to equity
- 0.91
- Debt ₹8.42 Cr
- EPS (TTM)
- −₹6.73
- OPM (TTM)
- −39.8%
- Net margin −30.2%
- Sales growth
- −79.4%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 3.96
- EV/EBITDA −20.6
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −13.2%.
- Quarterly sales down 79.4% on a year ago.
- 45% below its 52-week high.
- Interest coverage of only −96.3×.
About Skybiotech Healthcare
Skybiotech Healthcare Limited engages in the manufacturing and trading of pharmaceuticals and allied products in India. The company produces drugs, formulations, medicines, chemicals, aroma, allopathic drugs, herbal drugs, and surgical items. It also deals in shares and securities, as well as provides consultancy and assistance services in selling the goods of foreign clients. The company was formerly known as Kapil Cotex Limited and changed its name to…
- Headquarters
- Aurangabad
- Sector
- Industrials
- ISIN
- INE393H01016
- Website
- kapilcotexlimited.com
Price range
- Avg volume (3M)
- 102
- 1-year return
- minus 29.7%
- From 52-week high
- minus 45.5%
Peers
We couldn’t find listed peers for this company.
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 2.4 | 1.9 | 1 | 1.8 | 0.5 | |
| 2.3 | 2.1 | 1.4 | 2.7 | 1 | |
| 0.1 | −0.2 | −0.4 | −0.9 | −0.5 | |
| 3.1% | −11.8% | −45.7% | −48.1% | −106.4% | |
| 0 | 0 | 0.1 | 0.2 | 0.1 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| −0 | −0.3 | −0.5 | −0.9 | −0.6 | |
| – | – | – | 64.4% | – | |
| −0 | −0.3 | −0.5 | −0.3 | −0.6 | |
| -0.25 | -1.29 | -1.29 | -1.59 | -2.56 |
Profit & loss
- ROE
- −13.2%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| – | – | 7 | 7.1 | |
| – | – | 9.1 | 8.5 | |
| −0.1 | −0.1 | −2.1 | −1.5 | |
| – | – | −30.0% | −20.6% | |
| 0 | 2 | 0.1 | 0.1 | |
| – | – | – | 0 | |
| 0 | 0 | 0.5 | 0.5 | |
| 0 | – | 0.1 | 0.2 | |
| −0 | 1.9 | −2.4 | −1.7 | |
| 1.8% | 18.1% | 2.3% | 33.0% | |
| −0 | 1.5 | −2.4 | −1.1 | |
| -2.32 | 3.67 | -14.18 | -6.70 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1 | 1.9 | 1.9 | 1.9 | |
| 2.4 | 8.9 | 7.1 | 6.1 | |
| – | – | 7.8 | 9.1 | |
| 0.6 | 0.7 | 3.3 | 2.3 | |
| 4.1 | 11.5 | 20.1 | 19.4 | |
| 0 | 0 | 8.8 | 8.4 | |
| 3.7 | 2.6 | 2.1 | 1.9 | |
| 0 | 8.4 | −0.3 | −0.6 | |
| 0.3 | 0.5 | 9.4 | 9.8 | |
| 4.1 | 11.5 | 20.1 | 19.4 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −0.4 | −1.3 | −1 | −1.5 | |
| 0.4 | 3.6 | −9.6 | 0 | |
| – | 6.1 | 1.2 | 1.2 | |
| 0 | 8.4 | −9.4 | −0.3 | |
| – | – | −0.3 | −0 | |
| −0.4 | −1.3 | −1.4 | −1.5 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.